Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 9:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Gossamer Bio USA, Inc. Clear all
Completed Phase 1 Interventional

GB004 in Adult Subjects With Active Ulcerative Colitis

NCT03860896
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
GB004, Placebo
Drug
Lead sponsor
GB004, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Monroe, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 10, 2026, 9:35 AM EDT
Suspended Phase 3 Interventional

Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07181382
View directory record Official record
Conditions
Pulmonary Hypertension Associated With Interstitial Lung Disease
Interventions
Placebo, Seralutinib, Generic Dry Powder Inhaler
Drug · Device
Lead sponsor
GB002, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Fresno, California • Albuquerque, New Mexico • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 10, 2026, 9:35 AM EDT
Terminated Phase 1 Interventional

GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma

NCT05242146
View directory record Official record
Conditions
CNS Lymphoma
Interventions
GB5121
Drug
Lead sponsor
GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 10, 2026, 9:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1A Safety Trial of Inhaled PK10571 (GB002)

NCT03473236
View directory record Official record
Conditions
Safety Issues
Interventions
GB002, Generic Dry Powder Inhaler, Placebo
Drug · Device
Lead sponsor
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 10, 2026, 9:35 AM EDT
Completed Phase 2 Interventional Results available

GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

NCT04456998
View directory record Official record
Conditions
Pulmonary Artery Hypertension
Interventions
GB002 (seralutinib), Placebo, Generic Dry Powder Inhaler
Drug · Device
Lead sponsor
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
36
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 10, 2026, 9:35 AM EDT
Terminated Phase 2 Interventional

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

NCT04816604
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
GB002 (seralutinib), Generic Dry Powder Inhaler
Drug · Device
Lead sponsor
Gossamer Bio USA, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
15
States / cities
Sacramento, California • Santa Barbara, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 10, 2026, 9:35 AM EDT
Completed Phase 2 Interventional Results available

GB001 in Adult Participants With Chronic Rhinosinusitis

NCT03956862
View directory record Official record
Conditions
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP), Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Interventions
GB001, Placebo
Drug
Lead sponsor
GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
29
States / cities
Tucson, Arizona • Jonesboro, Arkansas • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 10, 2026, 9:35 AM EDT
Completed Phase 1 Interventional

Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension

NCT03926793
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
GB002, Placebo, Generic Dry Powder Inhaler
Drug · Device
Lead sponsor
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
La Jolla, California • Sacramento, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 10, 2026, 9:35 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

NCT05934526
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Placebo, Seralutinib, Generic Dry Powder Inhaler
Drug · Device
Lead sponsor
GB002, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
50
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 10, 2026, 9:35 AM EDT
Terminated Phase 1 Interventional

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

NCT04060342
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma
Interventions
GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
Drug
Lead sponsor
GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 10, 2026, 9:35 AM EDT
Completed Phase 2 Interventional Results available

GB001 in Adult Subjects With Moderate to Severe Asthma

NCT03683576
View directory record Official record
Conditions
Asthma
Interventions
GB001, Placebo
Drug
Lead sponsor
GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
47
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 10, 2026, 9:35 AM EDT
Recruiting Phase 3 Interventional

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

NCT06274801
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Seralutinib, Gereic Dry Powder Inhaler
Drug · Device
Lead sponsor
Gossamer Bio USA, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
33
States / cities
Fresno, California • Los Angeles, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 10, 2026, 9:35 AM EDT
Terminated Phase 2 Interventional Results available

A Study With GB004 in Adult Subjects With Active Ulcerative Colitis (UC)

NCT04556383
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
GB004, Placebo
Drug
Lead sponsor
GB004, Inc.
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Encinitas, California • Lancaster, California • Baton Rouge, Louisiana + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 10, 2026, 9:35 AM EDT